The decision was arrived at a meeting called by prime minister Manmohan Singh on Monday to end the deadlock on the issue between finance and commerce and industry ministries, two officials privy to developments told ET.
Finance minister P Chidambaram and commerce, industry minister Anand Sharma and health minister Ghulam Nabi Azad attended the meeting. Foreign Investment Promotion Board (FIPB) will decide on foreign investment proposals till the time competition law is amended, one official said.
The law ministry will examine if the conditions agreed through inter-ministerial consultations to protect interests of Indian consumer can be incorporated in the competition law, the second official said.
The government had in October last year said all foreign acquisitions in the pharmaceuticals sector would require FIPB approval, changing a 10-yearold policy that had all investment in the sector on the automatic route.
The tighter policy came after health ministry, some parliamentarians, NGOs and section of the industry expressed fears that the spate of buyouts of Indian drug companies by multinationals in recent years could undermine public health by reducing availability of low-cost medicines for Indians.
Daiichi Sankyo had purchase of Ranbaxy while Abbott took over domestic formulation business of Piramal Healthcare and Shanta Biotech was acquired by Sanofi Aventis of France.
All greenfield investments were left on the automatic route. It was decided that FIPB would clear pharma sector proposals for six months, but after that the jurisdiction would go to the Competition Commission of India once enabling changes in the competition law are made.
This led to a logjam as FIPB did not have the detailed rules that could be followed while clearing brownfield pharma FDI proposals to ensure public health interests were protected.
An inter-ministerial group headed by additional secretary in DEA Shaktikanta Das was set up to frame the rules after which FIPB clearedRs 3,000 crore worth of investment proposals last month.
The panel suggested conditions such as commitment by the foreign investor to manufacture and make available essential drugs post acquisition for five years and also to increase R&D expenditure by 5% for diseases prevalent in India.
The detailed guidelines were not notified because of differences between the ministries involved. The finance ministry wanted that only proposals involving more than 49% FDI should go to FIPB.
The department of industrial policy and promotion, the nodal body for FDI policy, and health ministry wanted that all brownfield proposals should require FIPB nod. Prime minister had to step in to resolve the impasse.
Read More News on
Download The Economic Times News App to get Daily Market Updates & Live Business News.
- Honeywell invests in Trinity Mobility
- Abu Dhabi Investment Authority and Saudi Arabia’s Public Investment Fund to invest $1b in Jio fibre assets
- Investing in US stocks? Investment guru says India will generate higher alpha
- How to invest in shares
- EPFO redeeming ETF investments?
- Is it the right time to invest in pharma funds?
3 Comments on this Story
Sachin Pethkar2910 days ago
Anyway health of economy and people, we are handing over to foreign players. Before doing so we should ensure a efficient regulatory body for it. Pharma sector is close to heart of people and there are maximum chances of exploitation as we are not able to determine what could be the fair price of a medicine.
Suresh Kamath2912 days ago
The Pharma companies need a huge investment for the future technology changes happening in the field hence it is a good move to allow FDI in Pharma.
The Health of its people is the prime responsibility of the Nation and they should benefit from this move and hope their living conditions will improve sooner than later..
Renu Parmar2912 days ago
FDI is fine so long as it brings in better technology, better practices .But if it is a garb for takeovers of our companies to further the interests of only the investor , then there is every reason to scrutinize such 'investments'. The CCI must prove that they can actually do this effectively. If not , the FIPB route is the only answer.